Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531541 | 1.00 | CYP3A4 (0.55) | CYP3A4CA12CA1CA2CA7 | |
| SCHEMBL5665783 | 0.86 | CYP3A4 (0.56) | CYP3A4CA12CA1CA2CA7 | |
| SCHEMBL5665782 | 0.86 | CYP3A4 (0.56) | CYP3A4CA12CA1CA2CA7 | |
| SCHEMBL6222428 | 0.85 | APP (0.58) | MAPTHTTESR1ALOX5CYP1A1 | |
| SCHEMBL6222426 | 0.85 | APP (0.58) | MAPTHTTESR1ALOX5CYP1A1 | |
| SCHEMBL1269174 | 0.85 | MAPT (0.67) | TTRDPP4MAPTMAOBHTT | |
| SCHEMBL1269172 | 0.85 | MAPT (0.67) | TTRDPP4MAPTMAOBHTT | |
| SCHEMBL1689725 | 0.84 | CA12 (0.67) | CYP3A4CA12CA1CA2CA7 | |
| SCHEMBL1689727 | 0.84 | CA12 (0.67) | CYP3A4CA12CA1CA2CA7 | |
| SCHEMBL3116132 | 0.84 | CA12 (0.55) | CYP3A4CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | CYP3A4 446/4885CA12 4749/4885CA1 4795/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | CYP3A4 446/4885CA12 4749/4885CA1 4795/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | CYP3A4 446/4885CA12 4749/4885CA1 4795/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | CYP3A4 446/4885CA12 4749/4885CA1 4795/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | CYP3A4 446/4885CA12 4749/4885CA1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.